Evaluation of the Safety, Tolerability, and Efficacy of the Pan-KRAS Inhibitor LY4066434 in Patients with KRAS Mutant Advanced Solid Tumors

The primary objective of this study is to characterize the **safety**, **tolerability**, and **efficacy** of the pan-KRAS inhibitor LY4066434 in participants with **KRAS mutant advanced solid tumors**. This is clinically relevant as KRAS mutations are prevalent in various solid tumors and are associated with poor prognosis and resistance to standard therapies. Understanding the safety and efficacy of LY4066434 could provide valuable insights into potential therapeutic options for this challenging patient population.

The clinical trial involves a total of **717 participants** diagnosed with **KRAS mutant solid tumors**. The study population includes both male and female subjects, with an age range spanning from 18 to 65 years. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided information regarding the main objective of the trial or the principal inclusion criteria. The selection process for the trial population is not explicitly described, and no additional demographic or health status details are available.

The clinical trial is designed to evaluate the **safety**, tolerability, and efficacy of the pan-KRAS inhibitor LY4066434 in participants with **KRAS mutant solid tumors**. This study is structured as a Phase 1 trial, which is typically the initial phase in clinical research focusing on assessing the safety profile of a new investigational drug. The trial will employ a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated recruitment start date is February 3, 2025, with the trial expected to conclude by January 1, 2030, indicating a comprehensive duration to thoroughly assess the investigational product.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a thorough assessment of the participant's medical history and current health status. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits. These visits are designed to monitor the participants' response to the treatment, assess any adverse effects, and ensure adherence to the study protocol. The end-of-study visit will mark the conclusion of the participant's involvement, where final evaluations will be conducted to gather comprehensive data on the investigational drug's impact.

The expected length of participant involvement will vary depending on individual response and the overall study timeline, but it is anticipated to span several months to years, given the trial's duration. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial's design and procedures are meticulously crafted to ensure the collection of robust data while prioritizing participant safety and ethical standards.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatments comprehensively.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on February 3, 2025, with an estimated completion date of January 1, 2030. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize various parameters such as **biomarker** levels or symptom improvement scores to gauge initial efficacy signals. The methods for measuring and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes collected at predetermined timepoints. The trial's efficacy assessments will be conducted in accordance with standard clinical trial protocols, ensuring rigorous data collection and analysis to evaluate the investigational product's potential therapeutic effects.